Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Levodopa/carbidopa intestinal gel infusion can improve camptocormia in Parkinson's disease.

Morales-Briceño H, Mahant N, Duma S, Martin A, Griffith J, Tsui D, Fung VS.

Parkinsonism Relat Disord. 2019 Jun 10. pii: S1353-8020(19)30271-8. doi: 10.1016/j.parkreldis.2019.06.010. [Epub ahead of print] No abstract available.

PMID:
31221564
2.

You shall not pass! Gut bacteria can convert levodopa to dopamine.

Morales-Briceño H, Fung VSC.

Mov Disord. 2019 Jul;34(7):986. doi: 10.1002/mds.27737. Epub 2019 Jun 17. No abstract available.

PMID:
31206796
3.

Teaching Video NeuroImages: Cold-induced laryngeal pseudomyotonia in Isaacs syndrome.

Morales-Briceño H, Perez JR, Balint B, Fung VSC.

Neurology. 2019 Jun 4;92(23):e2734. doi: 10.1212/WNL.0000000000007613. No abstract available.

PMID:
31160414
4.

Myoclonus-dystonia caused by GNB1 mutation responsive to deep brain stimulation.

Jones HF, Morales-Briceño H, Barwick K, Lewis J, Sanchis-Juan A, Raymond FL, Stewart K, Waugh MC, Mahant N, Kurian MA, Dale RC, Mohammad SS.

Mov Disord. 2019 Jul;34(7):1079-1080. doi: 10.1002/mds.27708. Epub 2019 Apr 29. No abstract available.

PMID:
31034681
5.

Parkinsonism in PGK1 deficiency implicates the glycolytic pathway in nigrostriatal dysfunction.

Morales-Briceño H, Ha AD, London K, Farlow D, Chang FCF, Fung VSC.

Parkinsonism Relat Disord. 2019 Apr 5. pii: S1353-8020(19)30198-1. doi: 10.1016/j.parkreldis.2019.04.004. [Epub ahead of print]

PMID:
30975619
6.

Deep Brain Stimulation as Management of Generalized Dystonia in the 18p Deletion Syndrome.

Duma SR, Fois AF, Morales-Briceño H, Fong MWK, Colebatch JG, Colley A, McMaster J, Mahant N.

Mov Disord Clin Pract. 2019 Feb 25;6(3):263-264. doi: 10.1002/mdc3.12729. eCollection 2019 Mar. No abstract available.

PMID:
30949560
7.

Author response: IgLON5-mediated neurodegeneration is a differential diagnosis of CNS Whipple disease.

Morales-Briceño H, Fung V.

Neurology. 2019 Mar 12;92(11):544-545. doi: 10.1212/WNL.0000000000007088. No abstract available.

PMID:
30858248
8.

Paroxysmal dyskinesias with drowsiness and thalamic lesions in GABA transaminase deficiency.

Morales-Briceño H, Chang FCF, Wong C, Mallawaarachchi A, Wolfe N, Pellegrino da Silva R, Hakonarson H, Sandaradura SA, Guo Y, Christodoulou J, Lagopoulos J, Grattan-Smith P, Fung VSC.

Neurology. 2019 Jan 8;92(2):94-97. doi: 10.1212/WNL.0000000000006744. No abstract available.

PMID:
30617166
9.

Tremor.

Morales-Briceño H, Fois AF, Fung VSC.

Handb Clin Neurol. 2018;159:283-301. doi: 10.1016/B978-0-444-63916-5.00018-5. Review.

PMID:
30482321
10.

24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson's disease.

Cruse B, Morales-Briceño H, Chang FCF, Mahant N, Ha AD, Kim SD, Wolfe N, Kwan V, Tsui DS, Griffith JM, Galea D, Fung VSC.

NPJ Parkinsons Dis. 2018 Nov 20;4:34. doi: 10.1038/s41531-018-0070-4. eCollection 2018.

11.

IgLON5-mediated neurodegeneration is a differential diagnosis of CNS Whipple disease.

Morales-Briceño H, Cruse B, Fois AF, Lin MW, Jiang J, Banerjee D, Grunstein R, Varikatt W, Rodriguez M, Shepherd C, Fung VSC.

Neurology. 2018 Jun 12;90(24):1113-1115. doi: 10.1212/WNL.0000000000005679. Epub 2018 May 16. No abstract available.

PMID:
29769372
12.

Beta-propeller-associated neurodegeneration can present with dominant or isolated parkinsonism.

Morales-Briceño H, Sanchez-Hernandez BE, Meyer E, Kurian MA, Fois AF, Rodriguez-Violante M, Leal-Ortega R, Perez-Lohman C, Mohammad S, Fung VSC.

Mov Disord. 2018 Apr;33(4):654-656. doi: 10.1002/mds.27294. Epub 2018 Feb 28. Review. No abstract available.

PMID:
29488265
13.

Isolated Nocturnal Occurrence of Orofacial Dyskinesias in N-methyl-D-aspartate Receptor Encephalitis-A New Diagnostic Clue.

Morales-Briceño H, Fung VSC.

Mov Disord Clin Pract. 2017 Sep 26;4(6):884-886. doi: 10.1002/mdc3.12535. eCollection 2017 Nov-Dec.

14.

Bobble-head doll syndrome in an 80-year-old man, associated with a giant arachnoid cyst of the lamina quadrigemina, treated with endoscopic ventriculocystocisternotomy and cystoperitoneal shunt.

Olvera-Castro JO, Morales-Briceño H, Sandoval-Bonilla B, Gallardo-Ceja D, Venegas-Cruz MA, Estrada-Estrada EM, Contreras-Mota M, Guinto-Balanzar G, Garcia-Lopez R.

Acta Neurochir (Wien). 2017 Aug;159(8):1445-1450. doi: 10.1007/s00701-017-3195-z. Epub 2017 May 9.

PMID:
28488069
15.

[Deep brain stimulation in Parkinson's disease. Preliminary outcomes].

Pérez-de la Torre RA, Calderón-Vallejo A, Morales-Briceño H, Gallardo-Ceja D, Carrera-Pineda R, Guinto-Balanzar G, Magallón-Barajas E, Corlay-Noriega I, Cuevas-García C.

Rev Med Inst Mex Seguro Soc. 2016;54 Suppl 2:S124-31. Spanish.

PMID:
27561015
16.

Frequency and clinical correlates of postural and striatal deformities in Parkinson's disease.

Cervantes-Arriaga A, Rodríguez-Violante M, Morales-Briceño H, Neri-Nani G, Millán-Cepeda R, Velázquez-Osuna S.

Clin Neurol Neurosurg. 2016 Mar;142:140-144. doi: 10.1016/j.clineuro.2016.02.003. Epub 2016 Feb 3.

PMID:
26866776
17.

Comparing the accuracy of different smell identification tests in Parkinson's disease: relevance of cultural aspects.

Rodríguez-Violante M, Gonzalez-Latapi P, Camacho-Ordoñez A, Martínez-Ramírez D, Morales-Briceño H, Cervantes-Arriaga A.

Clin Neurol Neurosurg. 2014 Aug;123:9-14. doi: 10.1016/j.clineuro.2014.04.030. Epub 2014 May 10.

PMID:
25012004
18.

Simultaneous Presentation of Ocular Flutter in Two Sisters.

Morales-Briceño H, Rodríguez-Violante M, Cervantes-Arriaga A.

Mov Disord Clin Pract. 2014 Jul 8;1(3):265-266. doi: 10.1002/mdc3.12064. eCollection 2014 Sep. No abstract available.

19.

Clinical, imaging, and molecular findings in a sample of Mexican families with pantothenate kinase-associated neurodegeneration.

Morales-Briceño H, Chacón-Camacho OF, Pérez-González EA, Arteaga-Vázquez J, Rodríguez-Violante M, Cervantes-Arriaga A, Pérez-Rodríguez L, Zenteno JC, Mutchinick OM.

Clin Genet. 2015 Mar;87(3):259-65. doi: 10.1111/cge.12400. Epub 2014 Jun 6.

PMID:
24712887
20.

Low specificity and sensitivity of smell identification testing for the diagnosis of Parkinson's disease.

Rodríguez-Violante M, Gonzalez-Latapi P, Camacho-Ordoñez A, Martínez-Ramírez D, Morales-Briceño H, Cervantes-Arriaga A.

Arq Neuropsiquiatr. 2014 Jan;72(1):33-7. doi: 10.1590/0004-282X20130190.

21.

A reappraisal of the ten steps test for identifying atypical parkinsonism.

Morales-Briceño H, Rodríguez-Violante M, Martinez-Ramirez D, Cervantes-Arriaga A.

Clin Neurol Neurosurg. 2014 Apr;119:1-3. doi: 10.1016/j.clineuro.2013.12.022. Epub 2014 Jan 10.

PMID:
24635916
22.

[Profile characterization of Parkinson's disease in Mexico: ReMePARK study].

Cervantes-Arriaga A, Rodríguez-Violante M, López-Ruiz M, Estrada-Bellmann I, Zuñiga-Ramírez C, Otero-Cerdeira E, Camacho-Ordoñez A, González-Latapi P, Morales-Briceño H, Martínez-Ramírez D.

Gac Med Mex. 2013 Sep-Oct;149(5):497-501. Spanish.

23.

Clinical determinants of health-related quality of life in Mexican patients with Parkinson's disease.

Rodríguez-Violante M, Cervantes-Arriaga A, Corona T, Martínez-Ramírez D, Morales-Briceño H, Martínez-Martín P.

Arch Med Res. 2013 Feb;44(2):110-4. doi: 10.1016/j.arcmed.2013.01.005. Epub 2013 Jan 30.

PMID:
23376054
24.

Opsoclonus myoclonus syndrome associated with GQ1b antibodies.

Morales-Briceño H, Rodríguez-Violante M, Cervantes-Arriaga A, Irani SR, Lees AJ, Silveira-Moriyama L.

Mov Disord. 2012 Nov;27(13):1615-6. doi: 10.1002/mds.25169. No abstract available.

PMID:
23192922
25.

Overweight is more prevalent in patients with Parkinson's disease.

Morales-Briceño H, Cervantes-Arriaga A, Rodríguez-Violante M, Calleja-Castillo J, Corona T.

Arq Neuropsiquiatr. 2012 Nov;70(11):843-6.

26.

[Premotor diagnosis of Parkinson's disease].

Morales-Briceño H, Cervantes-Arriaga A, Rodríguez-Violante M.

Gac Med Mex. 2011 Jan-Feb;147(1):22-32. Review. Spanish.

PMID:
21412393

Supplemental Content

Loading ...
Support Center